Publications scientifiques en 2025

Depuis le 15/05/2025
  1. Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials.
    Oliva A, Scavone C, Riccardi C, Bernardi FF, Salvo F, Mascolo A.
    Clin Transl Oncol. 2025
  2. Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case-time-control study.
    Bénard-Laribière A, Pambrun E, Kouzan S, Faillie JL, Bezin J, Pariente A.
    Thorax. 2025
  3. Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?
    Soeiro T, Daveluy A, Victorri-Vigneau C, Lapeyre-Mestre M, Micallef J.
    Therapie. 2025
  4. From regional signal to alert in addictovigilance.
    Daveluy A, Perino J, Gibaja V, Le Boisselier R, Batisse A, Miremont-Salamé G, Peyré A, Boucher A, Frauger E, Micallef J, Peyrière H.
    Therapie. 2025
  5. ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001.
    Perri-Plandé J, Miremont-Salamé G, Lapeyre-Mestre M, Perino J, Gibaja V, Daveluy A; French Addictovigilance Network.
    Therapie. 2025
  6. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Boulefaa D, Bagheri H, Salvo F, Rabier MB, Geniaux H, Lepelley M, Rocher F, Mahe J, Grandvillemuin A, Thai-Van H.
    Drug Saf. 2025
  7. Ethics and clinical research: How can the Ethics Committees (CPPs) and Committees for Research Ethics (CER) evolve?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2025
  8. Successful Linkage of Electronic Medical Records and National Health Data System in Type 2 Diabetes Research: Methodological Insights and Implications.
    Goff RL, Brice S, Contini A, Boussac M, Souche A, Belloc F, Coulombel N, Collin C, Gouverneur A, Molimard M.
    Pharmacoepidemiol Drug Saf. 2025
  9. Impact of psychedelics on craving in addiction: A systematic review.
    Chapron SA, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, Salvo F, Sessa B, Das R, Rolland B, Garcia-Romeu A, Auriacombe M.
    J Psychopharmacol. 2025
  10. Psychoactive cocktail consumption on Reunion Island: A case report.
    Guyon J, Maillot A, Bastard S, Weisse F, Daveluy A, Mété D.
    J Anal Toxicol. 2025
  11. Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study.
    Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski JL, Roustit M, Khouri C.
    Drug Saf. 2025
  12. Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.
    Talbot D, Diop A, Mésidor M, Chiu Y, Sirois C, Spieker AJ, Pariente A, Noize P, Simard M, Luque Fernandez MA, Schomaker M, Fujita K, Gnjidic D, Schnitzer ME.
    Stat Med. 2025
  13. Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.
    Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, Pariente A.
    Fundam Clin Pharmacol. 2025
  14. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demorgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  15. Changes in the Ambulatory Use of Antibiotics in France Due to the COVID-19 Pandemic in 2020-2022: A Nationwide Time-Series Analysis.
    Rousselot N, Brayan T, Dumartin C, Clément M, Pariente A.
    Ann Fam Med. 2025
  16. Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
    Swierczynski G, Canal-Raffin M, Tuduri L.
    Health Sci Rep. 2025
  17. The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.
    Vuotto F, Bru JP, Canaoui E, Caseris M, Chopin MCC, Cohen R, Diamantis S, Dihn A, Fillatre P, Gauzit R, Gillet Y, Jonville-Bera AP, Lafaurie M, Lesprit P, Lorrot M, Lourtet J, Maulin L, Poitrenaud D, Pariente A, Raymond J, Strady C, Stahl JP, Varon E, Welker Y, Bonnet E.
    Infect Dis Now. 2025
  18. Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Crisafulli S, Bate A, Brown JS, Candore G, Chandler RE, Hammad TA, Lane S, Maro JC, Norén GN, Pariente A, Russom M, Salas M, Segec A, Shakir S, Spini A, Toh S, Tuccori M, van Puijenbroek E, Trifirò G; Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Drug Saf. 2025
  19. The safety profile of fluoroquinolones.
    Jonville-Béra AP, Largeau B, di Meglio F, Pariente A.
    Infect Dis Now. 2025
  20. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  21. Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients: A Nationwide Population-Based Cohort Study.
    Gautier P, Elbaz M, Bezin J, Delmas C, Cherbi M, Bouisset F, Vindis C, Renoux A, Lafaurie M, Montastruc F.
    JACC Heart Fail. 2025